



For release at 9:00 AM ET, November 15, 2010

Contact: Judy Mathew, +1 (678) 892-8807

RFS Pharma Awarded Therapeutic Tax Credit and Announces the Approval by the U.S. FDA to Initiate a Phase 2 Study on the Anti-HIV drug Amdoxovir

Atlanta, GA, November 15, 2010 -- RFS Pharma, LLC, a clinical stage biopharmaceutical company, today announced the receipt of \$244,479 in tax credits under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program established as part of the Patient Protection and Affordable Care Act of 2010. The Company has received this credit for its lead clinical candidate amdoxovir for the treatment of HIV-1 infections. RFS Pharma also announced that its planned Phase 2 study of amdoxovir was approved by the Food and Drug Administration and will be initiated in 1Q2011.

"We are pleased to be a recipient of the Therapeutic Discovery Project, which bolsters small biopharmaceutical companies, by providing the necessary capital to support breakthrough scientific discoveries, medical research and innovation. We are delighted that the amdoxovir development program qualified for QTDP; this credit will be used to support some of the upcoming Phase 2 study activities," said Professor Raymond F. Schinazi, Founder and Chairman of the Board of Directors at RFS Pharma. The Phase 2 study will evaluate amdoxovir *versus* tenofovir disoproxil fumarate (tenofovir-DF, Viread[®]) in combination with zidovudine (Retrovir[®]) in treatment-experienced patients. Tenofovir-DF, marketed by Gilead Sciences, Inc. is currently one of the most widely used anti-HIV agents in the world.

Companies that received QTDP credits were selected jointly by the Department of Treasury and the Department of Health and Human Services. Since the available funds were substantially oversubscribed, the Department of Treasury further allocated the funds among the most qualified applicants. Under the program, a total of \$1 billion was allocated to small companies (250 or fewer employees) for biomedical research. The QTDP program evaluates each project for its potential to produce new therapies, address unmet medical needs, and reduce long-term health care costs. Additionally, the program targets therapeutic discovery projects that have the greatest potential to create and sustain high-quality, high-paying jobs in the U.S. and to advance U.S. competitiveness in life, biological and medical sciences. Only projects that have a reasonable potential to meet one or more of these goals is eligible to receive the credit.

About Amdoxovir

Amdoxovir (AMDX) is a nucleoside analog prodrug that is metabolized to its 2'-deoxyguanosine analog, DXG, which is a potent and selective inhibitor of HIV-1, including drug resistant viruses harboring M184V/I (to emerge from current first line therapy regimens) and thymidine analog mutations (TAMS). It is the only guanosine analog in clinical development for the treatment of HIV-1 infections. Amdoxovir has been safely administered to over 200 adults in seven Phase 1 and 2 studies. New data supports the development of a combination (amdoxovir with zidovudine) drug based on antiviral synergies and resistant repellent properties.

About RFS Pharma, LLC

RFS Pharma, LLC was founded in September 2004 and is located in a 26,500 sq. ft. state-of-the-art research facility in Tucker, Georgia. RFS Pharma is a privately owned biotech company committed to the discovery and development of antiviral agents and other human therapeutics. The company capitalizes on its expertise in nucleoside chemistry to develop drugs to combat infections caused by drug-resistant HIV and hepatitis viruses. RFS Pharma's lead product candidate is amdoxovir, which is in advanced Phase 2 clinical studies for the treatment of HIV-1 infections. In addition, the company has identified promising, early stage compounds for hepatitis infections, analogs that are effective against noroviruses, and has a proprietary novel nucleoside prodrug technology. For further information about RFS Pharma, please refer to our website, www.rfspharma.com.

Forward-looking Statements

"Safe Harbor" Statement: Any statements in this press release that relate to the Companies' expectations are forward-looking statements, within the meaning of the US Private Securities Litigation Reform Act of 1995. Since this information may involve risks and uncertainties and be subject to change at any time, the Companies' actual results may differ materially from expected results. The Companies disclaim any obligation to update the statements contained in this press release.

Retrovir[®] is a registered trademark of GlaxoSmithKline. Viread[®] is a registered trademark of Gilead Sciences, Inc.

SOURCE: RFS Pharma, LLC

###